<DOC>
	<DOCNO>NCT02554734</DOCNO>
	<brief_summary>Phase I open , randomize cross-over pharmacokinetic study .</brief_summary>
	<brief_title>Pharmacokinetic Study Healthy Volunteers</brief_title>
	<detailed_description>The purpose study investigate pharmacokinetics levodopa , carbidopa , 3-OMD ODM-104 repeat dos levodopa , carbidopa ODM-104 : open , randomize , multicenter study crossover design healthy male female .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>Written inform consent ( IC ) obtain Good general health ascertain detailed medical history physical examination Finnish speaking male females 1865 year age Normal weight define body mass index ( BMI ) 1930 kg/m2 ( BMI=weight/height m2 ) Weight least 55 kg Regular intestinal transit ( recent history recurrent constipation , diarrhea , intestinal problem , history major gastrointestinal surgery ) Sexually active study subject , unless surgically sterile must adhere proper form contraception ( hormonal contraception intrauterine device female partner , additional barrier method use least one partner ) first study treatment administration 3 month endofstudy visit Evidence clinically significant cardiovascular , renal , hepatic , haematological , gastrointestinal , pulmonary , metabolicendocrine , neurological psychiatric disease cancer ( except local nonmelanoma skin cancer ) within previous 2 year . Family history ( parent , sibling ) clinically significant cardiac conduction disease . Any condition require regular concomitant treatment ( include vitamin herbal product ) likely need concomitant treatment study . As exception , paracetamol occasional pain allow . Hormonal contraception hormone replacement therapy allow . Intake medication could affect outcome study . Any clinically significant abnormal laboratory value physical finding ( include ECG vital sign ) opinion investigator could interfere interpretation study result cause health risk subject he/she take part study . Known hypersensitivity active substance excipients drug . Pregnant lactate female . History vasovagal collapse vagal reaction unexplained reason within previous 2 year tendency vasovagal reaction blood sampling . HR &lt; 40 bpm &gt; 90 bpm supine position 10 min rest screen visit . At screen visit : systolic BP &lt; 90 mmHg &gt; 150 mmHg supine position 10 min rest diastolic BP &lt; 50 mmHg &gt; 90 mmHg supine position 10 min rest History anaphylactic/anaphylactoid reaction . Strong tendency motion sickness . Recent current ( suspect ) drug abuse . Recent current alcohol abuse ; regular drinking 21 unit per week ( male ) 16 unit per week ( female ) ( 1 unit = 4 cl spirit equivalent ) . Current use nicotine containing product 5 cigarette ( equivalent ) /day and/or inability refrain use nicotine containing product study ( screen visit endofstudy visit ) . Use caffeine contain beverage 600 mg caffeine/day and/or inability refrain use caffeine contain beverage 24 h first levodopa administration PK day ( day 7 ) collection 24 h PK sample morning day 8 . Blood donation loss significant amount blood within 90 day first study treatment administration . Participation investigational drug study administration investigational drug within 90 day first study treatment administration . Veins unsuitable repeated venipuncture cannulation . Predictable poor compliance inability communicate well study centre personnel . Inability participate treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>